Navigation Links
New Therapies Could Change Organ Transplants
Date:1/23/2008

Three reports show some patients went five years without anti-rejection drugs

WEDNESDAY, Jan. 23 (HealthDay News) -- Therapies that allow organ transplant recipients to stop taking powerful immunosuppressive drugs are starting to come to fruition.

"The next stage in the development of the transplant field is to completely withdraw those drugs and be able to have the lifesaving benefit of the transplant without the costs of the lifelong immunosuppressive drugs," said Dr. Samuel Strober, senior author of a paper describing one of these therapies and a professor of medicine at Stanford University School of Medicine.

The procedures, detailed in three reports in the Jan. 24 issue of the New England Journal of Medicine, won't expand the pool of donor organs, but they could greatly improve the outlook for those who receive organ transplants.

"We hope it will make a major difference in how transplants are done," said Dr. David H. Sachs, senior author of one of the studies and director of the Transplantation Biology Research Center at Massachusetts General Hospital in Boston. "Patients don't have to take immunosuppressor drugs all their lives, which is one of the major problems with transplants. The drugs are wonderful, but they have complications."

Those complications can include cancer and, ironically, kidney damage.

"Doctors did a great job about developing the use of transplants for people who had [organ] failure. The problem is that all people who get transplants have to go on lifelong immunosuppressor drugs, and those have lots of side effects, especially when used for very long periods of time. They also have substantial financial costs," Strober said. "It's a lot better to get these patients off the drugs."

Some 5 percent to 7 percent of organ transplant fail every year even if the individuals take their drugs religiously.

Both Sachs' and Strober's research involved "t
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Pipeline for New Obesity Therapies is Focus of New Report
2. MIT: Stem-cell therapies for brain more complicated than thought
3. Many prostate cancer patients receive improper or mismatched therapies
4. Thomson Scientific Publishes Who Is Making The Biggest Splash? - a Quarterly Review of Scientific Literature on Drugs and Therapies From July - September 2007
5. Telomerase enzyme structure provides significant new target for anti-cancer therapies
6. Studies attribute recent increase in multiple myeloma survival to novel therapies
7. Turning Pointe Therapeutic Riding Recognized for Excellence in Providing Equine-Assisted Therapies to People with Disabilities
8. Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference
9. Mayo researchers: complementary therapies help patients recover after heart surgery
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Therapies Could Change Organ Transplants
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... from a national survey of more than 149,000 Americans including ... that 25% of adults with disabilities, compared to 16 per ... was defined as having a Body Mass Index greater than ... limb mobility difficulties and those who had not received exercise ...
... on both mice and humans are showing why some people absorb ... if you eat a fatty meal or snack - a fried ... you absorb is strongly influenced by your genes. Experts know that ... fat diet is bad for you. But little has been discovered ...
... why surgery may trigger cognitive problems in some people ... older people develop problems with memory and other mental functions ... Cognitive Dysfunction (POCD).Often relatives will say that the person has ... was assumed, at first, that the anaesthetic was to blame. ...
... it is observed that a drug already being used ... an effective male contraceptive. Researchers hypothesized N-butyldeoxynojirimycin, or NB-DNJ, ... disease, might work// as a male contraceptive because it ... fertility. They tested their theory in an animal study ...
... new study, a protein in the eye has prevented and ... this could lead to promising treatments for other// autoimmune diseases ... from the Schepens Eye Research Institute in Boston found the ... drug. The drug can then prevent the onset of and ...
... researchers suggests that nurses and junior doctors can both carry ... competence.,There's a shortage of junior doctors in the UK// and ... to take over some of their roles. Researchers in Ireland, ... nurses assess people before surgery. ,They found that ...
Cached Medicine News:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
Allows for the organized storage of blocks that have been embedded using: Tissue Cassettes, Biopsy Cassettes, Mesh Cassettes, Mega Cassettes, Processing/Embedding Cassettes and Embedding Rings....
Unit System Slide Cabinet is constructed from hardwood for long lasting....
Shandon Slide File Storage System...
Shandon Microscope Slide Trays...
Medicine Products: